A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell - PubMed (original) (raw)
. 1998 Jun 4;393(6684):474-8.
doi: 10.1038/30989.
Affiliations
- PMID: 9624003
- DOI: 10.1038/30989
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
J P Ridge et al. Nature. 1998.
Abstract
To generate an immune response, antigen-specific T-helper and T-killer cells must find each other and, because they cannot detect each other's presence, they are brought together by an antigen-loaded dendritic cell that displays antigens to both. This three-cell interaction, however, seems nearly impossible because all three cell types are rare and migratory. Here we provide a potential solution to this conundrum. We found that the three cells need not meet simultaneously but that the helper cell can first engage and 'condition' the dendritic cell, which then becomes empowered to stimulate a killer cell. The first step (help) can be bypassed by modulation of the surface molecule CD40, or by viral infection of dendritic cells. These results may explain the long-standing paradoxical observation that responses to some viruses are helper-independent, and they evoke the possibility that dendritic cells may take on different functions in response to different conditioning signals.
Comment in
- Immunology. Licence to kill.
Lanzavecchia A. Lanzavecchia A. Nature. 1998 Jun 4;393(6684):413-4. doi: 10.1038/30845. Nature. 1998. PMID: 9623994 No abstract available.
Similar articles
- T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.
Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. Schoenberger SP, et al. Nature. 1998 Jun 4;393(6684):480-3. doi: 10.1038/31002. Nature. 1998. PMID: 9624005 - Engaging the CD40-CD40L pathway augments T-helper cell responses and improves control of Mycobacterium tuberculosis infection.
Sia JK, Bizzell E, Madan-Lala R, Rengarajan J. Sia JK, et al. PLoS Pathog. 2017 Aug 2;13(8):e1006530. doi: 10.1371/journal.ppat.1006530. eCollection 2017 Aug. PLoS Pathog. 2017. PMID: 28767735 Free PMC article. - Helper T cells, dendritic cells and CTL Immunity.
Behrens G, Li M, Smith CM, Belz GT, Mintern J, Carbone FR, Heath WR. Behrens G, et al. Immunol Cell Biol. 2004 Feb;82(1):84-90. doi: 10.1111/j.1440-1711.2004.01211.x. Immunol Cell Biol. 2004. PMID: 14984599 Review. - Central role of CD40 and its ligand in B lymphocyte responses to T-dependent antigens.
Gordon J, Katira A, Holder M, MacDonald I, Pound J. Gordon J, et al. Cell Mol Biol (Noisy-le-grand). 1994;40 Suppl 1:1-13. Cell Mol Biol (Noisy-le-grand). 1994. PMID: 7524882 Review.
Cited by
- RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy.
Shi JX, Zhang ZC, Yin HZ, Piao XJ, Liu CH, Liu QJ, Zhang JC, Zhou WX, Liu FC, Yang F, Wang YF, Liu H. Shi JX, et al. Mol Cancer. 2024 Sep 28;23(1):213. doi: 10.1186/s12943-024-02132-6. Mol Cancer. 2024. PMID: 39342168 Free PMC article. Review. - A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.
Tran B, Voskoboynik M, Bendell J, Gutierrez M, Lemech C, Day D, Frentzas S, Garrido-Laguna I, Standifer N, Wang F, Ferte C, Wang Y, Das M, Carneiro BA. Tran B, et al. Immunotherapy. 2024;16(11):759-774. doi: 10.1080/1750743X.2024.2359359. Epub 2024 Sep 12. Immunotherapy. 2024. PMID: 39264730 Free PMC article. Clinical Trial. - Neoantigen-specific T cell help outperforms non-specific help in multi-antigen DNA vaccination against cancer.
de Graaf JF, Pesic T, Spitzer FS, Oosterhuis K, Camps MGM, Zoutendijk I, Teunisse B, Zhu W, Arakelian T, Zondag GC, Arens R, van Bergen J, Ossendorp F. de Graaf JF, et al. Mol Ther Oncol. 2024 Jun 15;32(3):200835. doi: 10.1016/j.omton.2024.200835. eCollection 2024 Sep 19. Mol Ther Oncol. 2024. PMID: 39040850 Free PMC article. - Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.
Espinosa-Carrasco G, Chiu E, Scrivo A, Zumbo P, Dave A, Betel D, Kang SW, Jang HJ, Hellmann MD, Burt BM, Lee HS, Schietinger A. Espinosa-Carrasco G, et al. Cancer Cell. 2024 Jul 8;42(7):1202-1216.e8. doi: 10.1016/j.ccell.2024.05.025. Epub 2024 Jun 20. Cancer Cell. 2024. PMID: 38906155 - Advances in Composite Biofilm Biomimetic Nanodrug Delivery Systems for Cancer Treatment.
Meng Y, Chen S, Wang C, Ni X. Meng Y, et al. Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241250244. doi: 10.1177/15330338241250244. Technol Cancer Res Treat. 2024. PMID: 38693842 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials